Evotec and Yale University have entered into a strategic partnership to jointly assess and potentially pursue novel assays, screens and models, and in particular, exploratory drug targets and compounds in the areas of metabolic diseases, CNS, immunological diseases and cancer. The goal is to integrate Evotec’s drug discovery infrastructure with highly innovative biology at Yale to mature individual projects to a stage where they can be commercialized.   Dr. Cord Dohrmann, chief scientific ...